Vyome Holdings Inc

Vyome Holdings Inc operates with a capital structure that is entirely equity-funded, as evidenced by a debt-to-equity ratio of 0.00 and no long-term debt. The company maintains a strong liquidity position, with cash and equivalents amounting to $4.98 million, which is significantly higher than its total liabilities of $4.06 million, resulting in a current ratio of 1.99. However, the company's operating cash flow is negative at -$3.75 million, and free cash flow is -$10.47 million, indicating a reliance on external financing or asset sales to fund operations.

Profitability metrics are highly negative, with a net loss of $10.26 million and an operating loss of $10.45 million. Return on equity is -4.20%, and return on assets is -1.58%, both significantly below industry norms for biotechnology firms. The company's gross profit margin is 68.4%, but this is offset by high operating expenses, leading to a negative operating margin of -326.3%. These figures suggest that the company is not yet generating sustainable earnings and is likely in a high R&D phase.

Vyome's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment or geographic diversification increases the company's exposure to market-specific risks, particularly in the healthcare diagnostics sector.

The company's growth trajectory is uncertain, with no revenue growth data provided in the current period. Analysts have assigned a mean price target of $15.00, which is significantly higher than the current market price of $2.08, suggesting potential upside if the company can achieve profitability. However, the absence of revenue growth figures and the continued net losses indicate that the company is in an early-stage development phase.

Risk factors include the company's negative cash flows and lack of profitability, which could necessitate future equity or debt financing. The risk assessment indicates low dilution risk, but the company's reliance on external capital to fund operations could increase dilution potential if financing is required. No immediate filing-based liquidity or dilution flags were detected, but the company's negative operating cash flow and free cash flow suggest ongoing financial pressure.

Recent events include the publication of the latest financial data, which shows continued losses and negative cash flows. No recent filings or transcripts were provided that indicate significant changes in the company's strategic direction or financial outlook. The company's current financial position suggests that it is in a development phase, with a focus on R&D and commercialization of diagnostic solutions.